Investigating the Pathophysiology and Treatment Modalities for Autoimmune Disorders
DOI:
https://doi.org/10.63682/jns.v14i30S.8167Keywords:
Pathophysiology, Treatment Modalities, Autoimmune Disorders, diabetes, chronicAbstract
Background: Autoimmune disorders are becoming more common and have a large impact on patient's quality of life. Autoimmunity mechanisms and therapeutic intervention evaluation are needed to improve patient outcomes.
Objectives: The key mechanisms of autoimmune diseases (genetic predisposition, environmental triggers, immune dysregulation) and current therapeutic strategies are investigated. Furthermore, it explores emerging treatments and the challenges in clinical practice.
Methods: A review of the literature and recent studies on the genetic, molecular, and cytokine factors involved in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The therapeutic efficacy of biological therapies and personalized treatment approaches were evaluated.
Results: Major risk factors identified were genetic predisposition, infections, and smoking. Disease onset was found to be dependent on specific HLA alleles (HLA-DR3, HLA-DR4) and molecular mimicry. Chronic inflammation is caused by pro-inflammatory cytokines such as TNF-α and IL-6. Biologic therapies (infliximab and rituximab) proved to be effective therapeutics for SLE and RA. Biomarker early detection such as anti–nuclear antibodies (ANA) and rheumatoid factor (RF) helps in accurate diagnosis. New and more effective treatments—possibly for inherited traits, such as in rare diseases that once could never have been cured, and for diseases like asthma, in which new treatments such as JAK inhibitors and gene editing technologies could lead to dramatic improvement—could be found through precision medicine.
Conclusions: Multifactorial etiology of autoimmune diseases requires the development of patient-customized therapies involving genetic screening and combination therapies for improved patient outcomes. While progress has been made in biologics, there is still work to be done: biologics cost too much, patients do not adhere to treatment, and some populations in low and middle-income countries do not even have access to care. Novel therapeutic targets and epigenetic mechanisms, as well as the microbiome, need further research.
Downloads
Metrics
References
Ascherio, A., & Munger, K. L. (2007). Environmental risk factors for multiple sclerosis. Part I: the role of infection. Annals of Neurology, 61(4), 288-299.
Ball, J., Archer, S., & Ward, S. (2014). PI3K inhibitors as potential therapeutics for autoimmune disease. Drug Discovery Today, 19(8), 1195-1199.
Barry, C., & Raworth, K. (2002). Access to Medicines and the Rhetoric of Responsibility. Ethics & International Affairs, 16(2), 57-70.
Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121-141.
Blackstone, E. A., & Joseph, P. F. (2013). The economics of biosimilars. American health & drug benefits, 6(8), 469.
Boi, F., Pani, F., & Mariotti, S. (2017). Thyroid autoimmunity and thyroid cancer: review focused on cytological studies. European Thyroid Journal, 6(4), 178-186.
Bruce, B., & Fries, J. F. (2005). The health assessment questionnaire (HAQ). Clinical and experimental rheumatology, 23(5), S14.
Cooper, G. S., Bynum, M. L., & Somers, E. C. (2009). Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. Journal of autoimmunity, 33(3-4), 197-207.
Corrao, S., Argano, C., Calvo, L., & Pistone, G. (2015). The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice. Internal and Emergency Medicine, 10, 271-275.
Davidson, A., & Diamond, B. (2001). Autoimmune diseases. New England Journal of Medicine, 345(5), 340-350.
Dhillon, S. (2017). Tofacitinib: a review in rheumatoid arthritis. Drugs, 77, 1987-2001.
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
Fairweather, D., & Rose, N. R. (2004). Women and autoimmune diseases. Emerging infectious diseases, 10(11), 2005.
Gibbons, L. J., & Hyrich, K. L. (2009). Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs, 23, 111-124.
Hewagama, A., & Richardson, B. (2009). The genetics and epigenetics of autoimmune diseases. Journal of autoimmunity, 33(1), 3-11.
James, J. A., Kaufman, K. M., Farris, A. D., Taylor-Albert, E., Lehman, T. J., & Harley, J. B. (1997). An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. The Journal of Clinical Investigation, 100(12), 3019-3026.
Kelly, J. A., Moser, K. L., & Harley, J. B. (2002). The genetics of systemic lupus erythematosus: putting the pieces together. Genes & Immunity, 3(1), S71-S85.
Kono, D. H., & Theofilopoulos, A. N. (2006, October). Genetics of SLE in mice. In Springer seminars in immunopathology (Vol. 28, pp. 83-96). Springer-Verlag.
McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23), 2205-2219.
Munir, H., & McGettrick, H. M. (2015). Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem cells and development, 24(18), 2091-2100.
Osterberg, L., & Blaschke, T. (2005). Medication adherence. New England journal of medicine, 353(5), 487-497.
Rubbert-Roth, A. (2012). Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology, 51(suppl_5), v38-v47.
Saidha, S., Eckstein, C., & Calabresi, P. A. (2012). New and emerging disease-modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciences, 1247(1), 117-137.
Tan, Y. K., & Conaghan, P. G. (2011). Imaging in rheumatoid arthritis. Best practice & research Clinical rheumatology, 25(4), 569-584.
Verhoeven, A. C., Boers, M., & Tugwell, P. (1998). Combination therapy in rheumatoid arthritis: updated systematic review. British journal of rheumatology, 37(6), 612-619.
Yamamoto, K., Okada, Y., Suzuki, A., & Kochi, Y. (2015). Genetic studies of rheumatoid arthritis. Proceedings of the Japan Academy, Series B, 91(8), 410-422.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
